Display options
Cite
Bariola JR, McCreary EK, Wadas RJ, et al. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infect Dis. 2021;8(7):ofab254doi: 10.1093/ofid/ofab254.
Bariola, J. R., McCreary, E. K., Wadas, R. J., Kip, K. E., Marroquin, O. C., Minnier, T., Koscumb, S., Collins, K., Schmidhofer, M., Shovel, J. A., Wisniewski, M. K., Sullivan, C., Yealy, D. M., Nace, D. A., Huang, D. T., Haidar, G., Khadem, T., Linstrum, K., Seymour, C. W., Montgomery, S. K., Angus, D. C., & Snyder, G. M. (2021). Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open forum infectious diseases, 8(7), ofab254. https://doi.org/10.1093/ofid/ofab254
Bariola, J Ryan, et al. "Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection." Open forum infectious diseases vol. 8,7 (2021): ofab254. doi: https://doi.org/10.1093/ofid/ofab254
Bariola JR, McCreary EK, Wadas RJ, Kip KE, Marroquin OC, Minnier T, Koscumb S, Collins K, Schmidhofer M, Shovel JA, Wisniewski MK, Sullivan C, Yealy DM, Nace DA, Huang DT, Haidar G, Khadem T, Linstrum K, Seymour CW, Montgomery SK, Angus DC, Snyder GM. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infect Dis. 2021 May 17;8(7):ofab254. doi: 10.1093/ofid/ofab254. eCollection 2021 Jul. PMID: 34250192; PMCID: PMC8241472.
Copy Download .nbib Format: NLM
Share it on

Open Forum Infect Dis. 2021 May 17;8(7):ofab254. doi: 10.1093/ofid/ofab254. eCollection 2021 Jul.

Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Open forum infectious diseases

J Ryan Bariola, Erin K McCreary, Richard J Wadas, Kevin E Kip, Oscar C Marroquin, Tami Minnier, Stephen Koscumb, Kevin Collins, Mark Schmidhofer, Judith A Shovel, Mary Kay Wisniewski, Colleen Sullivan, Donald M Yealy, David A Nace, David T Huang, Ghady Haidar, Tina Khadem, Kelsey Linstrum, Christopher W Seymour, Stephanie K Montgomery, Derek C Angus, Graham M Snyder

Affiliations

  1. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  2. Department of Emergency Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  3. Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  4. Wolff Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  5. Division of Cardiology, Dept of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  6. UPMC Health System Office of Healthcare Innovation, Pittsburgh, Pennsylvania, USA.
  7. Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  8. Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  9. Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

PMID: 34250192 PMCID: PMC8241472 DOI: 10.1093/ofid/ofab254

Abstract

BACKGROUND: Monoclonal antibody treatment may prevent complications of coronavirus disease 2019 (COVID-19). We sought to quantify the impact of bamlanivimab monoclonal antibody monotherapy on hospitalization and mortality among outpatients at high risk of COVID-19 complications.

METHODS: In this observational study we compared outpatients who received bamlanivimab monoclonal antibody from December 9, 2020 to March 3, 2021 to nontreated patients with a positive polymerase chain reaction or antigen test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the same period who were eligible for monoclonal antibody treatment. The primary outcome was 28-day hospitalization or all-cause mortality, and the secondary outcome was hospitalization or emergency department visit without hospitalization. The risk-adjusted odds of study outcomes comparing bamlanivimab treated and untreated patients was determined using 1:5 propensity matching and multivariable logistic regression.

RESULTS: Among 232 patients receiving bamlanivimab matched with 1160 comparator patients, the mean age was 67 years, 56% were female, and 196 (14%) of patients experienced hospitalization or mortality. After adjustment for propensity to receive treatment, bamlanivimab treatment was associated with a significantly reduced risk-adjusted odds of hospitalization or mortality within 28 days (odds ratio [OR], 0.40; 95% confidence interval [95% CI], 0.24-0.69;

CONCLUSIONS: Bamlanivimab monoclonal antibody monotherapy was associated with reduced hospitalizations and mortality within 28 days among outpatients with mild to moderate COVID-19.Use of bamlanivimab monotherapy for outpatients with mild to moderate COVID-19 infection was associated with reductions in hospitalizations and mortality within 28 days. Benefit was strongest in those age 65 years or older.

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Keywords: COVID-19; SARS-CoV-2; bamlanivimab; monoclonal antibodies

References

  1. JAMA Surg. 2020 Jun 1;155(6):e200416 - PubMed
  2. PLoS Med. 2015 Oct 06;12(10):e1001885 - PubMed
  3. JAMA. 2021 Feb 16;325(7):632-644 - PubMed
  4. N Engl J Med. 2021 Jan 21;384(3):238-251 - PubMed
  5. Multivariate Behav Res. 2011 May;46(3):399-424 - PubMed
  6. Sci Transl Med. 2021 May 12;13(593): - PubMed
  7. Ann Intern Med. 2020 Nov 17;173(10):773-781 - PubMed
  8. Front Physiol. 2021 Jan 12;11:571416 - PubMed
  9. N Engl J Med. 2021 Jan 21;384(3):229-237 - PubMed
  10. JAMA. 2020 May 26;323(20):2052-2059 - PubMed
  11. Am J Respir Crit Care Med. 2021 Jan 1;203(1):54-66 - PubMed
  12. Clin Infect Dis. 2021 Apr 13;: - PubMed

Publication Types

Grant support